OraSure Technologies, Inc. Stock

Equities

OSUR

US68554V1089

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 03:59:48 2024-06-04 pm EDT 5-day change 1st Jan Change
4.64 USD -1.49% Intraday chart for OraSure Technologies, Inc. -3.93% -43.41%
Sales 2024 * 189M Sales 2025 * 166M Capitalization 348M
Net income 2024 * -13M Net income 2025 * -15M EV / Sales 2024 * 0.31 x
Net cash position 2024 * 290M Net cash position 2025 * - EV / Sales 2025 * 2.09 x
P/E ratio 2024 *
-25.8 x
P/E ratio 2025 *
-23 x
Employees 638
Yield 2024 *
-
Yield 2025 *
-
Free-Float 96.1%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.38%
1 week-3.93%
Current month-1.90%
1 month-15.64%
3 months-32.66%
6 months-36.35%
Current year-43.41%
More quotes
1 week
4.59
Extreme 4.5925
4.84
1 month
4.59
Extreme 4.5925
5.59
Current year
4.59
Extreme 4.5925
8.45
1 year
4.38
Extreme 4.375
8.45
3 years
2.62
Extreme 2.62
13.57
5 years
2.62
Extreme 2.62
19.75
10 years
2.62
Extreme 2.62
23.01
More quotes
Managers TitleAgeSince
Chief Executive Officer 50 22-06-03
Director of Finance/CFO 52 22-08-07
Chief Operating Officer - 22-06-30
Members of the board TitleAgeSince
Director/Board Member 61 19-08-10
Director/Board Member 64 20-04-05
Chairman 61 17-06-21
More insiders
Date Price Change Volume
24-06-04 4.64 -1.49% 728 887
24-06-03 4.71 -0.42% 906,478
24-05-31 4.73 +0.64% 709,287
24-05-30 4.7 +0.43% 578,382
24-05-29 4.68 -3.11% 737,255

Delayed Quote Nasdaq, June 04, 2024 at 12:17 pm EDT

More quotes
OraSure Technologies, Inc. provides point-of-care and home diagnostic tests, sample management solutions, and microbiome laboratory and analytical services. The Company's product portfolio is divided into diagnostics products and sample management solutions. Its business consists of the development, manufacture, marketing and sale of diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products including immunoassays and other in vitro diagnostic tests that are used on other specimen types. Its diagnostic products include tests for diseases including COVID-19, HIV and Hepatitis C that are performed on a rapid basis at the point of care, and tests for drugs of abuse that are processed in a laboratory. Its business also includes molecular sample management solutions and services that are used by clinical laboratories, direct-to-consumer laboratories, researchers, pharmaceutical companies, and animal health service and product providers.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
4.71 USD
Average target price
6.625 USD
Spread / Average Target
+40.66%
Consensus